A large retrospective study presented at the 2026 Annual Scientific Meeting of the American Society of Colon and Rectal Surgeons has found that surgical intervention for inflammatory bowel disease (IBD) has become markedly less common over the past two decades, coinciding with the wider use of biologic therapies. The findings suggest that modern medical treatment may be altering the long-term trajectory of Crohn’s disease and ulcerative colitis, reducing reliance on major operations.
Background
Surgery has long been a necessary part of IBD management, particularly for patients whose disease does not respond adequately to medical therapy. Procedures such as J-pouch reconstruction for ulcerative colitis and stricturoplasty for Crohn’s disease have traditionally been reserved for severe or refractory cases involving complications like strictures, fistulas, or uncontrolled inflammation. Over the past twenty years, the treatment landscape has shifted substantially with the introduction and expansion of biologic therapies, which target specific inflammatory pathways rather than broadly suppressing the immune system. Researchers have increasingly sought to understand whether this shift in medical management has translated into fewer patients requiring invasive surgical procedures.
Key Findings
The researchers analysed data from more than 25,500 adults with IBD, comparing two cohorts: those treated between 2004 and 2014, and those treated between 2014 and 2024. According to the study authors, this comparison revealed a clear downward trend in the frequency of major IBD-related operations across the two time periods. Procedures including J-pouch creation for ulcerative colitis and stricturoplasty for Crohn’s disease became notably less common in the more recent cohort, a pattern the researchers attributed to the growing use of advanced biologic therapies during that period. The study authors described this as evidence that modern medical treatments are not simply controlling symptoms but may be meaningfully altering disease progression, delaying or, in some cases, preventing the need for surgical intervention altogether. Alongside this positive trend, the researchers noted an emerging workforce concern: as IBD-related surgeries become rarer, colorectal surgeons may face fewer opportunities to develop and maintain expertise in these complex procedures, raising questions about future training needs.
Clinical Relevance
For people living with IBD, these findings point towards a treatment landscape increasingly focused on early, sustained disease control rather than reactive management of complications. For clinicians, the data reinforce the case for timely use of effective medical therapy as a strategy to preserve bowel function and avoid major surgery where possible. The researchers’ observation about surgical training also carries implications for services planning future IBD care, since maintaining specialist surgical expertise remains essential for the smaller number of patients who will still require operative intervention. The study adds to a broader body of evidence linking modern biologic treatment with improved long-term outcomes in IBD.
Reference
American Society of Colon and Rectal Surgeons. Biologic therapy associated with declining rates of IBD-related surgery: findings presented at the 2026 Annual Scientific Meeting. General Surgery News. 2026.
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.